Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Archives

You are currently viewing the 2011 archives
Click here to return to the current data set

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: 8-HOUR BAYER

« Back to Dashboard

Summary for Tradename: 8-HOUR BAYER


Clinical Trials for: 8-HOUR BAYER

Vardenafil ODT (Orally Disintegrating Tablet) - Nifedipine Interaction Study
Status: Completed Condition: Erectile Dysfunction

Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection
Status: Completed Condition: Abscess; Wound Infection; Diabetic Foot; Ulcer

A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs
Status: Completed Condition: Infectious Diseases

Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667
Status: Terminated Condition: Congestive Heart Failure

Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent
Status: Not yet recruiting Condition: Magnetic Resonance Imaging

Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery
Status: Completed Condition: Blood Loss, Surgical; Postoperative Hemorrhage

Naproxen Sodium/ASA Platelet Study
Status: Not yet recruiting Condition: Pain

Study Evaluation the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction for 10 Weeks
Status: Completed Condition: Erectile Dysfunction

A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP.
Status: Recruiting Condition: Immune Thrombocytopenic Purpura

GLucobay M OBservation Study for Efficacy and Safety in Treatment of Type-2 Diabetes Patients
Status: Completed Condition: Type 2 Diabetes

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
TABLET, EXTENDED RELEASE; ORAL016030Approved Prior to Jan 1, 1982DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology